Sangamo Therapeutics, Inc. announced that interim clinical data from the company's inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8, 2019 at the Hyatt Regency Orlando in Orlando, Florida. The WORLDSymposium program includes two platform presentations from clinical trials of Sangamo's zinc finger nuclease (ZFN)-mediated in vivo genome editing product candidates, SB-318 and SB-913, which are being evaluated for the treatment of mucopolysaccharidosis type I (MPS I) and type II (MPS II), respectively; CHAMPIONS: A Phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome); and EMPOWERS: A Phase 1/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler Syndrome). The SB-913 (MPS II) presentation is expected to include interim data on safety and biochemical measurements at up to 24 weeks from six subjects enrolled in the three dose cohorts of the CHAMPIONS Study. The SB-318 (MPS I) presentation is expected to describe the scientific rationale for SB-318, the clinical trial design, and preliminary safety and biochemical measurements at up to four weeks from the first three patients enrolled in the EMPOWERS Study. Sangamo expects to provide additional SB-913 and SB-318 updates in 2019 as data accumulate and mature in these clinical development programs.